Starton Therapeutics Inc CEO Pedro Lichtinger tells Proactive the privately-held, Paramus, New Jersey-based group has selected a subcutaneous (under the skin) lenalidomide formulation as the lead formulation candidate for its continuous subcutaneous delivery system (STAR-LLD SC) for chronic lymphocytic leukemia, which is a type of cancer of the blood and bone marrow, and other hematological malignancies.
Lichtinger says STAR-LLD SC clinical trial materials are expected to be shipped in the second quarter of 2021 for initiation of Phase 1/2 clinical studies for CLL in the second half of 2021. This moves the group closer to producing a product to benefit patients.
